|
|
Article: Oculus Innovative Sciences Announces Agreement With Bayer (Sichuan) Animal Health Co. Ltd. for Development of Microcyn(R) Technology Use in Chinese Animal Market.
- Article from:
- Business Wire
- Article date:
- June 23, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PETALUMA, Calif. -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn[R] Technology platform that is intended to treat infections in chronic and acute wounds, announced today an agreement with Bayer (Sichuan) Animal Health Co. Ltd. for development of the Microcyn[R] Technology for use in the Chinese animal market.
As part of the agreement, Bayer (Sichuan) Animal Health Co. Ltd. will be responsible for securing Chinese regulatory approval for the use of Microcyn Technology in both the Chinese companion animal and food animal markets. Upon receipt of the ...